Navigation Links
ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent
Date:4/21/2009

FREDERICK, Md., April 21 /PRNewswire/ -- ImQuest BioSciences and Arisyn Therapeutics jointly announced today the successful acquisition of funding from the National Institutes of Health to support the development of novel small molecule therapeutics for the treatment of hepatitis C virus (HCV) infection. ImQuest scientists will investigate the therapeutic potential and mechanism of action of ATI-0810 (Formerly PG301029) and a series of related chemical compounds. PG301029 is a highly novel transcriptional inhibitor of HCV replication, yielding a significant reduction of viral RNA synthesis in infected cells, and laboratory studies have demonstrated the compound to be less toxic and more active than the FDA approved agent ribavirin. Preliminary in vivo toxicology studies indicate that the compound is well tolerated and has a pharmacokinetic profile appropriate for drug development. The ImQuest research team will be led by Principal Investigator Todd B. Parsley, Ph.D., Director of Hepatitis Virus Research. The funded studies will permit ImQuest to define other potent transcriptional inhibitors of HCV, investigate the mechanism of action of the active molecules and provide additional rationale for the development of a combination anti-HCV therapy using the lead molecules.

"We believe that the addition of a novel agent such as PG301029 to the current standard of care for HCV infected individuals will greatly enhance the percentage of patients that are able to achieve a robust and durable antiviral response to therapy," said Dr. Robert W. Buckheit, Jr., Executive Vice President of ImQuest. "Our data provide adequate rationale for the expedited development of PG301029 for HCV infection, and provide a platform to identify novel cellular and viral targets for future antiviral therapeutic development efforts."

The research continues the collaborative scientific partnership between ImQuest and Arisyn Therapeutics for the development of Arisyn Therapeutic's portfolio of antiviral and anticancer products.

ImQuest BioSciences Inc. is a privately held U.S. company located in Frederick, Maryland, is a leading provider of anti-infective therapeutic and microbicide development services to the biotechnology and pharmaceutical industry.

Arisyn Therapeutics Inc. is a privately held virtual biotechnology company headquartered in Frederick Maryland with a mission of identifying novel first in class inhibitors for infectious diseases and cancer based on their transcription targeted therapeutic agent platform.

    For further information regarding this press release please contact:
    Robert W. Buckheit, Jr., Ph.D.
    Executive Vice President and Chief Scientific Officer
    ImQuest Life Sciences, Inc.
    301-696-0274
    rbuckheit@imquest.com


'/>"/>
SOURCE ImQuest BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410
2. ImQuest Receives Two Year Phase 2 SBIR Grant to Develop Pyrimidinedione Product as an Anti-HIV Topical Microbicide
3. ImQuest Scientists Present Important HIV Microbicide Development Results at Microbicides 2008 in Delhi, India
4. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
5. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY
6. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
7. Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
8. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
9. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
10. YM BioSciences Announces Milestone Payment For Approval Of Nimotuzumab In The Philippines And Indonesia
11. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017  Vanderbilt University Medical ... patients in Nashville , Tennesse have ... Esophageal Sphincter Stimulation for GERD (LESS GERD) trial. The ... provide long-term reflux control by restoring normal function to ... 65 million people in the United States ...
(Date:4/19/2017)... SAN DIEGO , April 19, 2017 /PRNewswire/ ... ("Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new ... today announced the closing of its previously announced ... common stock at a public offering price of ... commissions and estimated offering expenses payable by Sorrento.  ...
(Date:4/19/2017)... April 19, 2017  New research provides evidence that an ... according to a study released today that will be presented ... in Boston , April 22 to ... treatment of Parkinson,s disease, the oral drug levodopa has long ... longevity. But as the disease progresses, the effects of the ...
Breaking Medicine Technology:
(Date:4/29/2017)... Slidell, Louisiana (PRWEB) , ... April 29, 2017 ... ... and Brookshire’s Grocery Company to the list of fine retailers selling biodegradable, hanging ... company. H.E.B., a large supermarket chain headquartered in San Antonio, Texas, operates ...
(Date:4/28/2017)... Washington, DC (PRWEB) , ... April 28, 2017 ... ... Unplanned Pregnancy (The National Campaign) announces its support for the Access to ... by Sen. Jeanne Shaheen (D-NH) and Rep. Jackie Speier (D-CA), will help to ...
(Date:4/28/2017)... ... April 28, 2017 , ... Beginning in 2017, Ridgecrest Herbals will be phasing ... the popular ClearLungs Extra Strength formula. To ensure that the effectiveness of Clear Lungs ... ways:, , Removal of the homeopathic element , ...
(Date:4/28/2017)... ... April 28, 2017 , ... Date aired: ... , “Computers are everywhere and they’re here to stay,” said Sharon Kleyne on ... and Your Health on Voice America sponsored by Nature’s Tears® EyeMist®. So she ...
(Date:4/28/2017)... ... April 28, 2017 , ... Children and adolescents who ... experiences than children in the general population. That’s because foster care is designed ... family challenges. While no fault of their own, youth who have experienced trauma ...
Breaking Medicine News(10 mins):